title: Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears.
abstract: Chemotherapy has made an essential contribution to cancer treatment in recent decades despite its adverse effects. As cancer survivors have increased, concern about ex-patient lifespan has become more important too. Doxorubicin is an effective anti-neoplastic drug that produces a cardiotoxic effect. Cancer survivors who received doxorubicin became more vulnerable to cardiac disease than the normal population did. Many efforts have been made to prevent cardiac toxicity in patients with cancer. However, current therapies cannot guarantee permanent cardiac protection. One of their main limitations is that they do not promote myocardium regeneration. In this review, we summarize and discuss the promising use of mesenchymal stem cells for cardio-protection or cardio-regeneration therapies and consider their regenerative potential without leaving aside their controversial effects on tumor progression.
authors.affiliation: Centro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, Av. Las Condes 12348, Lo Barnechea, Santiago, 7690000, Chile.
authors.forename: Fernando
authors.initials: F
authors.lastname: Ezquer
authors.affiliation: Facultad Ciencias de la Salud, Universidad San Sebastián, Lota 2465, 1° piso Edificio A, Providencia, Santiago, 7500000, Chile.
authors.forename: Jaime
authors.initials: J
authors.lastname: Gutiérrez
authors.affiliation: Centro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, Av. Las Condes 12348, Lo Barnechea, Santiago, 7690000, Chile.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Ezquer
authors.affiliation: Fundación Arturo Lopez Pérez, Rancagua, Providencia, Santiago, 7500000, Chile.
authors.forename: Christian
authors.initials: C
authors.lastname: Caglevic
authors.affiliation: Department of Physiology, School of Medicine of Ribeirão Preto, University of São Paulo, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
authors.forename: Helio C
authors.initials: HC
authors.lastname: Salgado
authors.affiliation: Centro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, Av. Las Condes 12348, Lo Barnechea, Santiago, 7690000, Chile. scalligaris@udd.cl.
authors.forename: Sebastián D
authors.initials: SD
authors.lastname: Calligaris
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000209:etiology / Q000628:therapy*; D004317:Doxorubicin / Q000633:toxicity; D006321:Heart / Q000502:physiology; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology; D017382:Reactive Oxygen Species / Q000378:metabolism; D012038:Regeneration
chemical_list: D000903:Antibiotics, Antineoplastic; D017382:Reactive Oxygen Species; D004317:Doxorubicin